Low Dose IV ketamine offers hope for pain in Ehlers Danlos Syndrome by Pradeep Chopra, MD

Unlocking Relief: How Low-Dose IV Ketamine Offers Hope for Pain in Ehlers-Danlos Syndrome

by

Pradeep Chopra, MD

Living with Ehlers-Danlos Syndrome (EDS) often means navigating a daily battle with chronic, often debilitating pain. For many patients, traditional pain medications like opioids or NSAIDs offer limited relief and come with unwanted side effects. But a growing body of clinical experience is showing promise with an unconventional ally: low-dose intravenous (IV) ketamine.

Let’s explore why this novel therapy is gaining traction in the management of EDS-related pain.

What Is Ehlers-Danlos Syndrome?

EDS is a group of connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Many patients suffer from neuropathic pain, muscle spasms, and central sensitization, making treatment complex and frustrating. Over time, the nervous system becomes more reactive—a phenomenon known as central sensitization, where even gentle touch can provoke intense pain.

Enter Ketamine: A Unique Pain-Modulator

Ketamine is best known as an anesthetic, but at low sub-anesthetic doses, it acts as a powerful NMDA receptor antagonist. This property allows it to "reset" the nervous system, making it particularly effective for pain that has a strong central sensitization component—something very common in EDS.

Why Low-Dose IV Ketamine for EDS?

✅ 1. Modulates Central Sensitization

Low-dose ketamine reduces the “wind-up” phenomenon in the spinal cord—dampening the exaggerated response to pain stimuli that’s typical in EDS patients.

✅ 2. Rapid Onset of Relief

While many oral medications take weeks to show benefit, ketamine infusions can offer noticeable pain relief within hours to days of treatment—especially valuable during pain flares.

✅ 3. Opioid-Sparing Effects

Ketamine can reduce reliance on opioids, which is crucial in a population often at risk for opioid-related side effects like GI dysfunction or tolerance.

✅ 4. Improved Mood and Sleep

Many EDS patients also experience comorbid depression, anxiety, and insomnia. Ketamine's unique mechanism also boosts glutamate and BDNF, supporting mood and cognitive function—an added bonus for whole-person care.

✅ 5. Minimal Respiratory Depression

Unlike opioids, ketamine does not suppress respiratory drive, making it safer for outpatient use in appropriately selected patients.

What Does a Low-Dose IV Ketamine Infusion Look Like?

• Dose Range: Typically 0.1–0.5 mg/kg per hour
• Duration: Sessions often last 1–4 hours
• Frequency: Varies by patient—some benefit from a series of infusions followed by maintenance dosing
• Setting: Usually administered in a specialized clinic with monitoring

Is It Safe?

When administered under the care of experienced pain physicians, low-dose IV ketamine is well-tolerated. Side effects like mild dissociation, dizziness, or nausea can occur but are usually short-lived and manageable.

Who Is a Good Candidate?

• Patients with moderate to severe pain not responsive to conventional therapies
• Those experiencing neuropathic or centrally mediated pain
• Individuals looking to reduce opioid use
• Patients with flare-based pain patterns or autonomic dysregulation

A Word of Caution

Ketamine is not a cure-all. Its effects can vary between individuals, and it’s most effective when integrated into a multidisciplinary treatment plan that includes physical therapy, lifestyle strategies, and psychological support.

‍

1. Niesters, M., Martini, C., & Dahan, A. (2014). Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol, 77(2), 357–367.
2. Woolf, C. J. (2011). Central sensitization: implications for the diagnosis and treatment of pain. Pain, 152(3 Suppl), S2–S15.
3. Sigtermans, M. J., van Hilten, J. J., Bauer, M. C., et al. (2009). Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain, 145(3), 304–311.
4. Bell, R. F., Eccleston, C., & Kalso, E. A. (2003). Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev, (1), CD003351.
5. Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015). Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med, 66, 509–523.
6. Feder, A., Parides, M. K., Murrough, J. W., et al. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry, 71(6), 681–688.
7. Hijazi, Y., Boulieu, R. (2002). Contribution of CYP3A4, CYP2B6 and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos, 30(7), 853–858.
8. Schwartzman, R. J., Patel, M., Grothusen, J. R., & Alexander, G. M. (2009). Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain, 147(1-3), 107–115.

‍